Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Celestone Clear all
Completed Phase 1 Interventional

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

NCT03122353
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene and betamethasone suspension, Taclonex, Placebo
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
34
States / cities
Hot Springs, Arkansas • Fremont, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream

NCT03892564
View directory record Official record
Conditions
Phototoxicity
Interventions
MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation, MC2-01 vehicle, no irradiation, Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

NCT01222247
View directory record Official record
Conditions
Pregnancy, Respiratory Distress Syndrome, Pregnancy Outcomes, Preterm Birth
Interventions
Betamethasone, Placebo
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
2,831 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
17
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Sep 7, 2026, 1:27 AM EDT
Terminated Phase 3 Interventional Results available

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

NCT02527421
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DFD01 Spray
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
12 Years to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Encino, California • Irvine, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

NCT03731091
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%, Enstilar® foam (LEO Pharma Inc.), Placebo of Calcipotriene/ betamethasone dipropionate topical foam
Drug · Other
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
30
States / cities
Encinitas, California • Fountain Valley, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Results available

A Double Blind Study Comparing Hyaluronic Acid, Corticosteroid and Placebo During Arthrocentesis for Temporomandibular Joint (TMJ) Dysfunction

NCT01524913
View directory record Official record
Conditions
Temporomandibular Joint Dysfunction, Pain, Arthrocentesis
Interventions
Hyaluronic acid, Corticosteroid, Lactated Ringers
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Cinncinati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Sep 7, 2026, 1:27 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?

NCT02939742
View directory record Official record
Conditions
PPROM, Respiratory Distress Syndrome in Premature Infants
Interventions
Betamethasone, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects

NCT02038569
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 80185 gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Diego, California • Tampa, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

NCT01536886
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100, Betamethasone plus calcipotriol, Ointment vehicle, LEO 90100 vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
39
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

NCT03441789
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Enstilar, Vehicle, Otezla
Drug
Lead sponsor
L.H. Kircik, M.D.
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Sacramento, California • Louisville, Kentucky • Rockville, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test

NCT03004339
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
SOR007 Ointment 2.0%, SOR007 Ointment 1.0%, SOR007 Ointment 0.3%, SOR007 Ointment 0.15%, SOR007 Ointment Placebo, Taclonex® Ointment
Drug
Lead sponsor
DFB Soria, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 4 Interventional

Enstilar in Combination With Biologic Agents

NCT03080545
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar 0.005%-0.064% Topical Foam
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 4 Interventional

Betamethasone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosynovitis

NCT02604537
View directory record Official record
Conditions
DeQuervain Tendinopathy
Interventions
betamethasone, Ketorolac
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rescue Antenatal Steroids and Pulmonary Function Tests in Preterm Infants

NCT00669383
View directory record Official record
Conditions
Respiratory Compliance, Functional Residual Capacity, Pulmonary Function Testing
Interventions
betamethasone, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

NCT02070965
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DFD01 Spray, Comp01 Lotion
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
12
States / cities
Encinitas, California • Encino, California • Santa Rosa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Sep 7, 2026, 1:27 AM EDT
Recruiting Phase 4 Interventional

Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study

NCT04207931
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Topical steroid class I-II, Triamcinolone Acetonide, Doxycyline, Minoxidil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

NCT04734197
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%, Betamethasone Sodium Phosphate 0.01%, Placebo Comparator: Vehicle, Cyclosporine 0.05% Ophthalmic Emulsion, Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Azusa, California • Hemet, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 7, 2026, 1:27 AM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)

NCT05981118
View directory record Official record
Conditions
ICD10 Code L40.9 for Psoriasis
Interventions
Betamethasone dipropionate 0.05%, Tapinarof
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream

NCT03899064
View directory record Official record
Conditions
Photoallergy
Interventions
Induction: Application of MC2-01 Cream, irradiation, Induction: Application of MC2-01 Cream, no irradiation, Induction: Applications of MC2-01 vehicle, irradiation, Induction: Applications of MC2-01 vehicle, no irradiation, Challenge: Application of MC2-01 Cream, irradiation, Challenge: Application of MC2-01 Cream, no irradiation, Challenge: Applications of MC2-01 vehicle, irradiation, Challenge: Applications of MC2-01 vehicle, no irradiation, Challenge: Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

LEO 90100 in the Treatment of Psoriasis Vulgaris

NCT01536938
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100, Calcipotriol, Betamethasone
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
33
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream

NCT03462927
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
MC2-01 Cream, CAL/BDP combination
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Sweetwater, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients

NCT03848871
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 7, 2026, 1:27 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

NCT05535738
View directory record Official record
Conditions
Skin Inflammation, Allergic Contact Dermatitis
Interventions
Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab, Adalimumab, Ustekinumab, Guselkumab, Canakinumab, Sarilumab, Triamcinolone Acetonide, Betamethasone Valerate, Fluticasone Propionate, Microneedle, Suction blistering, Skin punch biopsy
Drug · Other · Device + 1 more
Lead sponsor
Wei-Che Ko
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 7, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Antenatal Betamethasone Compared to Dexamethasone - "BETACODE TRIAL"

NCT00418353
View directory record Official record
Conditions
Respiratory Distress Syndrome, Intraventricular Hemorrhage, Neonatal Mortality
Interventions
Betamethasone(Celestone soluspan) and Dexamethasone
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2007 · Synced Sep 7, 2026, 1:27 AM EDT